NDAINHALATIONAEROSOL, METERED
Approved
Mar 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
MEDIHALER-ISO (isoproterenol sulfate) by AbbVie is beta-adrenergic agonist with very low affinity for alpha‑adrenergic receptors. First approved in 1956.
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEDIHALER-ISO is an inhaled metered-dose aerosol containing isoproterenol sulfate, a beta-adrenergic agonist with minimal alpha-receptor affinity. It is indicated for bronchospasm relief and respiratory conditions requiring rapid bronchodilation via inhalation.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating team focus on managed decline and retention strategies.
Mechanism of Action
beta-adrenergic agonist with very low affinity for alpha‑adrenergic receptors.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MEDIHALER-ISO supports 1,435 linked job opportunities across commercial, operations, and legal functions, with emphasis on supply chain and sales roles reflecting LOE stage priorities. Working on this legacy product provides exposure to managed decline strategies, regulatory complexity, and transition planning—valuable experience for portfolio stewardship roles.
DirectorSpecialty Representative
Worked on MEDIHALER-ISO at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.